Evidence map›Paper›PMID 33385022›Full record

ArticleData in brief2021

RNA sequencing data of different grade astrocytoma cell lines.

Juliana Ferreira de Sousa, Patrick da Silva, Rodolfo Bortolozo Serafim, Ricardo Perecin Nociti, Cristiano Gallina Moreira, Wilson Araujo Silva, Valeria Valente

Open access · goldAbstract read
In one paragraph

Article in Data in brief, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Juliana Ferreira de SousaRadiation Oncology Branch, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892, United States.
Patrick da SilvaDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Rodovia Araraquara-Jaú, Km 01 - s/n, Campos Ville, Araraquara, SP 14800-903, Brazil.
Rodolfo Bortolozo SerafimDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Rodovia Araraquara-Jaú, Km 01 - s/n, Campos Ville, Araraquara, SP 14800-903, Brazil.
Ricardo Perecin NocitiNational Institute of Science and Technology in Stem Cell and Cell Therapy and Center for Cell-Based Therapy, Rua Tenente Catão Roxo, 2501, Monte Alegre, Ribeirão Preto, SP 14051-140, Brazil.
Cristiano Gallina MoreiraDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Rodovia Araraquara-Jaú, Km 01 - s/n, Campos Ville, Araraquara, SP 14800-903, Brazil.
Wilson Araujo SilvaNational Institute of Science and Technology in Stem Cell and Cell Therapy and Center for Cell-Based Therapy, Rua Tenente Catão Roxo, 2501, Monte Alegre, Ribeirão Preto, SP 14051-140, Brazil.
Valeria ValenteDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Rodovia Araraquara-Jaú, Km 01 - s/n, Campos Ville, Araraquara, SP 14800-903, Brazil.
Universidade Estadual Paulista (Unesp) · BRNational Cancer Institute · USUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astrocytomas are the most common and aggressive type of primary brain tumors in adults. The World Health Organization (WHO) assorts them into grades, from I to IV, based on histopathological features that reflect their malignancy [1]. Alongside with tumor progression, comes an increased proliferation, genomic instability, infiltration in normal brain tissue and resistance to treatments. The high genomic instability forges tumor cells enhancing key proteins that avoid cells from collapsing and favor therapy resistance [2]. To explore genes and pathways associated with tumor progression phenotypes we analyzed gene expression in a panel of non-tumor and glioma cell lines, namely: ACBRI371, non-tumor human astrocytes; HDPC, fibroblasts derived from dental pulp; Res186, Res259, Res286 and UW467 that include grade I, II and III astrocytoma cell lines derived from pediatric tumors; and T98G, U343MG, U87MG, U138MG and U251MG, all derived from GBM (grade IV). We also profiled gene expression changes caused by exogenously induced replicative stress, performing RNA sequencing with camptothecin (CPT)-treated cells. Here we describe the RNA-sequencing data set acquired, including quality of reads and sequencing consistency, as well as the bioinformatics strategy used to analyze it. We also compared gene expression patterns and pathway enrichment between non-tumor

Indexed as

AstrocytomaCamptothecin (CPT)Gene expression profilingGlioblastomaReplicative stressRNAseqTumor progression

Identifiers

PMID33385022
PMCPMC7772531
OpenAlexW3111709586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.